Almitrine

This classification denotes a cns stimulant with the molecular formula C26H29F2N7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9A1222NBG4, chemically known as 1,3,5-triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n-di-2-propenyl- but generally known as almitrine, which bears US NIH Compound Identifier 33887. Almitrine comes in various forms, including bismesylate, bismethane sulfonate, dimesylate, dimethanesulfonate, and mesylate. European Medicines Agency schedules Almitrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05348MIG. The term ALMITRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules almitrine in its Anatomical Therapeutic Chemical (ATC) Classification. ALMITRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almitrine under HS 29336980 and SITC 51576. As of Q4 2014, ALMITRINE remains the US FDA Preferred Term for this commodity. Almitrine bears US NLM identifiers UMLS ID C0002164 and NCI Concept Code C74241. SMILES: FC1CCC(C(N2CCN(CC2)C2NC(NC(N2)NCC=C)NCC=C)C2CCC(F)CC2)CC1.